Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $129.83 Consensus Target Price from Analysts

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has earned a consensus rating of “Moderate Buy” from the fifteen analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $129.8333.

A number of equities research analysts have recently weighed in on the company. Raymond James Financial reaffirmed a “strong-buy” rating and set a $131.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. JPMorgan Chase & Co. started coverage on Dianthus Therapeutics in a report on Friday, September 11th. They issued an “overweight” rating and a $135.00 price objective on the stock. Truist Financial raised their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Citigroup assumed coverage on shares of Dianthus Therapeutics in a research note on Friday, September 4th. They issued a “buy” rating and a $156.00 target price for the company.

Dianthus Therapeutics Trading Down 1.3%

NASDAQ DNTH opened at $101.12 on Friday. Dianthus Therapeutics has a 1-year low of $32.22 and a 1-year high of $117.88. The company has a market capitalization of $5.53 billion, a PE ratio of -24.37 and a beta of 1.24. The firm’s fifty day simple moving average is $107.04 and its 200-day simple moving average is $92.81.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The firm had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. As a group, analysts predict that Dianthus Therapeutics will post -3.81 EPS for the current year.

Insider Buying and Selling at Dianthus Therapeutics

In related news, Director Anne McGeorge sold 7,750 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $109.01, for a total value of $844,827.50. Following the completion of the sale, the director directly owned 1,250 shares in the company, valued at approximately $136,262.50. This represents a 86.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Simrat Randhawa sold 23,124 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total transaction of $2,460,624.84. Following the completion of the sale, the executive vice president owned 4,000 shares of the company’s stock, valued at $425,640. This represents a 85.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 253,678 shares of company stock worth $27,248,400 in the last ninety days. Company insiders own 3.02% of the company’s stock.

Hedge Funds Weigh In On Dianthus Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Arizona State Retirement System lifted its position in shares of Dianthus Therapeutics by 5.7% in the second quarter. Arizona State Retirement System now owns 10,141 shares of the company’s stock worth $989,000 after buying an additional 546 shares during the last quarter. Nykredit A S acquired a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at about $147,000. Amundi bought a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at approximately $287,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at approximately $1,033,000. Finally, Alyeska Investment Group L.P. lifted its holdings in Dianthus Therapeutics by 188.2% in the 2nd quarter. Alyeska Investment Group L.P. now owns 150,592 shares of the company’s stock worth $14,680,000 after purchasing an additional 98,345 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for complement-mediated diseases. The complement system is part of the immune system, and abnormal activation can contribute to autoimmune and inflammatory disorders. Dianthus is developing therapies designed to selectively inhibit complement activity while offering potentially durable treatment effects.

The company’s lead product candidate, DNTH103, is an investigational monoclonal antibody designed to inhibit C1s, a protein involved in the classical complement pathway.